Xencor (XNCR) Competitors $7.69 +0.17 (+2.26%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$7.69 0.00 (0.00%) As of 05/22/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. MIRM, APLS, ARWR, VCEL, NAMS, GMTX, AAPG, BLTE, HRMY, and DNLIShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), Harmony Biosciences (HRMY), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Mirum Pharmaceuticals Apellis Pharmaceuticals Arrowhead Pharmaceuticals Vericel NewAmsterdam Pharma Gemini Therapeutics Ascentage Pharma Group International Belite Bio Harmony Biosciences Denali Therapeutics Mirum Pharmaceuticals (NASDAQ:MIRM) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Is MIRM or XNCR more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Xencor -232.77%-30.92%-21.74% Does the MarketBeat Community favor MIRM or XNCR? Xencor received 373 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 76.40% of users gave Mirum Pharmaceuticals an outperform vote while only 73.13% of users gave Xencor an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13676.40% Underperform Votes4223.60% XencorOutperform Votes50973.13% Underperform Votes18726.87% Which has more volatility and risk, MIRM or XNCR? Mirum Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Do analysts rate MIRM or XNCR? Mirum Pharmaceuticals currently has a consensus target price of $60.73, suggesting a potential upside of 37.86%. Xencor has a consensus target price of $29.50, suggesting a potential upside of 283.62%. Given Xencor's higher possible upside, analysts clearly believe Xencor is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has better valuation and earnings, MIRM or XNCR? Xencor has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$379.25M5.75-$163.41M-$1.61-27.36Xencor$127.23M4.30-$126.09M-$3.06-2.51 Does the media prefer MIRM or XNCR? In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Xencor. MarketBeat recorded 20 mentions for Mirum Pharmaceuticals and 6 mentions for Xencor. Mirum Pharmaceuticals' average media sentiment score of 1.34 beat Xencor's score of 1.17 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Xencor on 11 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$547.31M$6.51B$5.35B$8.44BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-2.409.1526.9119.77Price / Sales4.29259.30390.06119.10Price / CashN/A65.8538.2534.62Price / Book0.706.476.794.52Net Income-$126.09M$144.21M$3.23B$248.23M7 Day Performance-6.49%2.64%1.99%0.77%1 Month Performance-28.00%4.80%11.45%13.45%1 Year Performance-68.70%-2.52%17.35%7.67% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.8594 of 5 stars$7.69+2.3%$29.50+283.6%-68.6%$547.31M$127.23M-2.40280MIRMMirum Pharmaceuticals4.0712 of 5 stars$44.89-0.3%$60.73+35.3%+68.0%$2.22B$379.25M-22.22140News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.2008 of 5 stars$17.67+1.3%$40.42+128.8%-59.2%$2.22B$775.84M-8.70770Analyst ForecastGap UpARWRArrowhead Pharmaceuticals3.517 of 5 stars$15.74+0.2%$42.13+167.6%-38.8%$2.17B$545.21M-3.04400News CoverageAnalyst ForecastAnalyst RevisionVCELVericel2.6795 of 5 stars$42.54+0.1%$60.86+43.1%-17.8%$2.14B$238.54M709.12300News CoveragePositive NewsAnalyst ForecastNAMSNewAmsterdam Pharma2.6685 of 5 stars$19.03+0.8%$43.00+126.0%-6.6%$2.09B$47.14M-10.124Positive NewsAnalyst DowngradeGMTXGemini TherapeuticsN/A$48.09+2.1%N/A+56.4%$2.08BN/A-48.0930High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$23.78+5.0%N/AN/A$2.07B$980.65M0.00600News CoveragePositive NewsGap DownBLTEBelite Bio2.0404 of 5 stars$65.00+0.9%$96.67+48.7%+43.5%$2.07BN/A-58.5610News CoverageAnalyst DowngradeAnalyst RevisionHRMYHarmony Biosciences4.7845 of 5 stars$35.91+2.4%$52.78+47.0%+13.1%$2.06B$744.85M17.02200Positive NewsDNLIDenali Therapeutics4.4937 of 5 stars$13.91+0.9%$33.71+142.4%-31.9%$2.02B$330.53M-5.04430Gap Down Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Vericel Alternatives NewAmsterdam Pharma Alternatives Gemini Therapeutics Alternatives Ascentage Pharma Group International Alternatives Belite Bio Alternatives Harmony Biosciences Alternatives Denali Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
